Alcresta is committed to developing rare disease, enzyme-based products helping to address fat malabsorption (often due to exocrine pancreatic insufficiency) in patients who are enterally fed at home or in the hospital. Our RELiZORB® (immobilized lipase) cartridge contains iLipase®, a patented microbead/enzyme technology that breaks down fat for absorption by the body.
RELiZORB® (immobilized lipase) is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. Please see Instructions for Use for full safety information at www.relizorb.com.